It's entirely possible that they would view this as a "convenience drug", that is, you take it 2 – 4X per year, rather than 26. Unless there is a major medical benefit that ALN-PCSsc brings to the table, payers won't pay a penny more for this drug than they'd pay for Praluent and/or Repatha. In fact, the addition of a new competitor might further strengthen the position of the payers to drive prices down even more. There is no doubt that ALN-PCSsc is an exciting new medicine and might prove to be a major breakthrough. But we are years away from realizing this potential and, even with successful completion of long and expensive clinical trials, it will still face major hurdles. It is a bit premature to confer upon it blockbuster status.